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A B S T R A C T
Introduction: Sleep quality, quantity and timing have been shown to impact glycaemic con-
trol, with a role in insulin sensitivity, glucose tolerance and HbA1C levels, in both diabetic
and non-diabetic populations. The aim of this study was to identify recommendations for
sleep assessment and management in international clinical practice guidelines focused on
type 2 diabetes mellitus management in adults.
Study design: Systematic Review.
Methodology: Clinical practice guidelines which focused on the management of type 2 dia-
betes mellitus in adults were included (n = 35). Two independent reviewers utilised the
Appraisal of Guidelines for Research and Evaluation tool (AGREE) II and a third reviewer
resolved any disagreements. Included guidelines were assessed for recommendations
about sleep in diabetes management (n = 14). Data were extracted on sleep recommenda-
tions ,themes were generated from the extracted data and narrative syntheses were cre-
ated.
Results: From 1114 identified papers, 35 guidelines met the inclusion criteria. Fourteen of
these guidelines included recommendations pertaining to sleep, which broadly fell into five
categories; sleep assessment, sleep as a therapeutic target, sleep and co-morbidities of type
2 diabetes mellitus, shift work and sleep and driving. Recommendations varied across
guidelines.
Conclusion: Few guidelines provided recommendations relating to assessment and man-
agement of sleep in type 2 diabetes care. Most of the recommendations were related to
obstructive sleep apnoea. However, few guidelines discussed sleep as a therapeutic inter-
vention for diabetes mellitus or described the potential importance of sleep quality and
duration in glycaemic control.
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1. Introduction
Diabetes is an increasing global health challenge affecting 8%
of the adult population worldwide [1]. The International Dia-
betes Federation (IDF) estimates that there will be 578 million
adults living with diabetes by 2030 and 700 million by 2045 [2].
There are multiple diabetes complications including
microvascular (retinopathy, nephropathy, and neuropathy)
and macrovascular (cardiovascular disease and stroke) diffi-
culties that translate to reduced quality of life and longevity
[3,4].
Lifestyle modification is the cornerstone for managing
type 2 diabetes mellitus (T2DM), the most prevalent type of
diabetes [5]. Diet, exercise, stress, and medication manage-
ment are key mediators and enablers of glycaemic control
[6]. These are strongly influenced by self-management
through individual behaviour and action [7]. Apart from the
traditional lifestyle factors, such as diet, physical activity,
and smoking, there is increasing awareness of the impact of
sleep behaviours and sleep disorders on glycaemic control.
Short sleep and sleep disturbance are common amongst peo-
ple with T2DM with approximately 39% sleeping less than
6.5 h per night [8], and 55% experiencing poor sleep quality
[9]. A number of systematic reviews have highlighted the
impact of sleep quantity and quality on glycaemic control in
both people with [10,11] and without [12] diabetes. Short
and long sleep duration have been identified as risk factors
for developing T2DM [12,13]. Sleep duration and quality [14]
are associated with decreased insulin sensitivity, increased
fasting plasma glucose [10,11], and elevated HbA1c [10,11].
Sleep duration of less than 6 h or>9 h is associated with
increased cardiometabolic risk in people with T2DM [15]. As
well as sleep duration, altered sleep timing associated with
shift work have also been associated with an increased risk
of T2DM [16] and poorer glycaemic control in those with
T2DM [17]. Furthermore,’catch up’ weekend sleep is not
enough to reverse the impeded insulin sensitivity seen in pro-
longed short sleep duration periods [18]. Obstructive sleep
apnoea (OSA) has also been implicated in dysregulated glu-
cose homeostasis and diabetes [19–24]. The mechanisms
accounting for OSA and metabolic disease include hypox-
aemia, sleep fragmentation and systemic inflammation [25–
28]. Optimal sleep quality and subsequent reduction in HbA1c
among people with type 2 diabetes has been associated with a
3% reduction in deaths, 2% reduction in myocardial infarction
and a 5% reduction in microvascular complications [11].
The assessment of sleep duration and quality can be
achieved through self-monitoring of sleep and its disorders
as well as specific clinical assessments conducted at home
or within the sleep laboratory [29]. These can be linked to a
range of specific measures to address issues with sleep dura-
tion and quality. Addressing sleep duration, quality, and sleep
disorders may provide an effective strategy to support opti-
mal glycaemic control. With the emerging body of evidence
on sleep and glycaemic control [11], this review explores the
extent to which recommendations for sleep assessment and
sleep management for people living with T2DM have been
incorporated into international clinical practice guidelines.
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Furthermore, for those guidelines that include recommenda-
tions relating to sleep, we aimed to identify the recommenda-
tions, assess methodological quality of the guidelines, the
levels of evidence underpinning the recommendations and
consistency of advice across guidelines. Assessment and
management of sleep in patients with T2DM is a quick, inex-
pensive process, which can support in optimising glycaemic
control.
2. Methods
This systematic review has been registered with PROSPERO
(registration number: CRD42020142136) and was conducted
according to PRISMA guidelines.
2.1. Eligibility criteria
This review considered any clinical practice guideline (CPG)
on the management of type 2 Diabetes Mellitus as per the def-
inition from the National Guideline Clearinghouse, ‘‘Clinical
practice guidelines are statements that include recommenda-
tions intended to optimize patient care that are informed by a
systematic review of evidence and an assessment of the ben-
efits and harms of alternative care options.” [30]. Clinical
practice guidelines that were evidence-based and published
by a professional society, government bodies, or national
and international diabetes associations that focused on the
treatment of T2DM in adults, were included in this study.
Clinical practice guidelines for the prevention of diabetes,
gestational diabetes, pre-diabetes, type 1 diabetes mellitus,
and specifically for T2DM in children, adolescents, and elderly
populations, were excluded. However, if a guideline covered
all populations, and a section addressed the management or
assessment of T2DM in adults, it was included. If a guideline
exclusively covered the management of diabetes co-
morbidities, then it was excluded. A guideline was excluded
if it was a draft, unpublished, a conference paper, included
position statements, an opinion piece, a discussion paper,
or a review and summary of a CPG where the full guideline
was available elsewhere. Any historical CPGs that had subse-
quently been updated, or published before 2010 were
excluded, as these were considered to be out of date with
respect to current clinical practice. Only CPGs written in Eng-
lish, or an English summary of CPG were included.
This review focused on diabetes management, lifestyle
factors, sleep (including OSA), and comorbidities linked with
sleep. Nocturnal hypoglycaemia was excluded, as the focus
of this study was to identify recommendations around sleep
assessment and sleep management.
2.2. Search strategy
The Guidelines International Network (GIN), Guideline Cen-
tral, National Heath & Medical Research Council (NHMRC),
National Institute for Health and Care Excellence (NICE), Scot-
tish Intercollegiate Guidelines Network (SIGN), and Google
were searched using the terms ‘‘type 2 diabetes mellitus”
and ‘‘clinical practice guidelines”. Websites of national and
international diabetes organisations were also hand
searched. The search was completed in September 2020.
Databases searches for published CPGs were conducted in
MEDLINE, CINAHL, and EMBASE, with the following search
string: (adult* OR ((MH ‘‘Adult”))) AND ((‘‘clinical practice
guideline*”) OR (‘‘clinical practice guidelines”) OR ((MH ‘‘Prac-
tice Guideline”) OR (MH ‘‘Practice Guidelines as Topic”))) AND
((‘‘type 2 diabetes”) OR (‘‘diabetes type 2”) OR (‘‘diabetes mel-
litus type 2”) OR (‘‘diabetes 2”) OR (‘‘non insulin dependent
diabetes”) OR (‘‘non insulin dependent diabetes mellitus”)
OR ((MH ‘‘Diabetes Mellitus, Type 2”)) OR T2DM). Publication
dates were limited to 2010–2020 and English language.
2.3. Study screening and selection
References were exported to Endnote, then duplicates
removed and hand-checked to remove additional duplicates.
Titles and abstracts were screened by one reviewer using
inclusion and exclusion criteria. The CPG titles were sourced
from these research articles, and full text CPGs were searched
via Google Search or the relevant international diabetes
associations.
2.4. Appraisal of guidelines
Fourteen CPGs which contained sleep recommendations were
independently appraised by two reviewers (Table 2) using the
AGREE-II instrument [65] Where there was disagreement
among reviewers, a third reviewer also appraised the guide-
line. The AGREE-II tool is used to assess the quality of CPGs,
and contains 23 items organised into six domains (Scope
and Purpose, Stakeholder Involvement, Rigour of Develop-
ment, Clarity of Presentation, Applicability, Editorial Indepen-
dence) [65]. A seven point Likert scale is used to answer each
question which ranges from strongly disagree (1) to strongly
agree (7), total score range 23–161. The final score assigned
to each guideline was an average of the reviewer’s scores.
Overall confidence in the guidelines were judged as follows:
‘the guideline was strongly recommended’ (four of six
domains  60%; ‘the guideline was recommended with mod-
ifications (at least two domains > 60%); ‘the guideline was not
recommended due to serious problems according to AGREE
criteria appraisal (three of six domains less than 30% or no
domain > 60%) [66]. Any bias in the guidelines were accounted
for in the appraisals.
2.5. Data extraction and synthesis
The following descriptive data were extracted from all 35
CPGs: country, guideline organisation/society/authors, guide-
lines name(s) (including whether the guideline was a new or
updated version), year of publication, target users, guideline
writers, guideline review process, and search strategy for evi-
dence (Table 1). Textual descriptive synthesis was undertaken
of all included CPGs (n = 14) to analyse the scope and context
of each guideline. Guidelines were initially read by one author
(MD) to identify content within the CPGs pertaining to sleep.
Another author (AS) extracted and coded relevant content to
separate data out into relevant domains. Each CPG was com-
pared across each domain for context and consistency of
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Table 2 – Quality appraisal according to AGREE for the 14 sleep studies.
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Japan, Japan Diabetes Society
(2016)
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Medicine, Diabetes Malaysia,
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content. Individual sleep-related recommendations were
graded based on the level of evidence provided within the
guideline to support the recommendation (Table 3). Grading
was based upon evidence rating levels for production of CPGs,
as per the American Association of Clinical Endocrinologists
[57]. Grade 1 evidence is comprised of randomised controlled
trials, grade 2 evidence is comprised of systematic reviews,
non-randomised controlled trials, cohort studies and case
controls studies, grade 3 evidence includes cross sectional
studies, surveillance studies, case series and case reports,
and grade 4 evidence includes expert opinion, consensus or
no evidence. Data extraction and syntheses was verified by
a second reviewer (MJ).
3. Results
3.1. Search and guideline characteristics
The systematic electronic database search strategy identified
1035 publications, with 786 remaining after duplicates were
removed. After screening titles and abstracts, 35 full text arti-
cles were assessed based on T2DM inclusion criteria, and six
were identified as CPGs (Fig. 1: PRISMA) [67]. Further system-
atic searching of guideline databases was conducted, and 91
articles were found based on T2DM inclusion criteria. Fifty-
seven articles were retrieved from the Guideline International
Network (GIN), 10 articles were identified through Guideline
central, while further hand searching identified 24 articles
for inclusion. From these 127 articles, 35 CPGs were identified
as relating to T2DM (Table 1). Guidelines were retrieved from
Australia, Belgium, Canada, China, Columbia, India, Japan,
Korea, Malaysia, Pakistan, Poland, Qatar, Scotland, Singapore,
South Africa, United Kingdom, United States of America
(USA), and from international collaborations. Of the 35
included CPGs focused on T2DM management, 14 mentioned
sleep within the guidelines (Table 2).
3.2. Methodological quality
The AGREE-II tool was used to assess methodological quality
of the included 14 sleep CPGs (Table 2). The domains with the
mean scores from highest to lowest, were Clarity and Presen-
tation (82.0%), Scope and Purpose (79.3%), Stakeholder
Involvement (61.0%), Rigour of Development (56.0%), Editorial
Independence (46.7%), and Applicability (46.0%). The mean
score for all domains combined, is 60.5%. Based on the overall
AGREE-II scores, guidelines were assigned a methodological
quality (Not recommended; recommended with modification;
strongly recommended). Seven guidelines were rated as
strongly recommended, six guidelines were rated as recom-
mended for use after modification, and one guideline was
not recommended.
3.3. Synthesis of recommendations
Fourteen guidelines included sleep in their recommendations
[34,38,42,43,46,48,50,52,55–57,60–62]. These CPGs were anal-
ysed and four major findings were identified regarding their
sleep-related content: (i) sleep as a risk factor for T2DM along
with sleep assessment in T2DM; (ii) sleep as a therapeutic tar-
get in T2DM; (iii) sleep and T2DM comorbidities; (iv) sleep and
driving in T2DM; and (v) shift work. Recommendations were
based on varied levels of evidence (Table 3).
3.3.1. Sleep assessment/ sleep as a risk factor for type 2
diabetes mellitus
Of the fourteen guidelines, eight included recommendations
for assessment of sleep quality, quantity and/or symptoms
of OSA [34,38,46,52,57,60–62]. Whilst some guidelines recom-
mended either initial or periodic assessment of sleep quality
and quantity and/or OSA [34,52,57,60,62], other guidelines
included sleep as a potential risk factor for diabetes without
providing any assessment recommendations [46]. Short and
long sleep duration was described as a risk factor for diabetes
in two CPGs [43,46]. Sleep apnoea was described as modifiable
risk factor for T2DM, OSAwas described as an independent or
modifiable risk factor for diabetes in two CPG [38], and OSA,
chronic sleep deprivation, and night-shift occupation were
described as risk factors for both pre-diabetes and T2DM
[57]. Several guidelines identified the prevalence of OSA
[60,61] especially among obese T2DM and the importance of
referring patients with potential OSA for specialist assess-
ment [61]. Increased prevalence of general sleep disorders in
those with T2DM compared to the general population was
noted in one CPG [38].
3.3.2. Sleep as a therapeutic target as a risk factor for type 2
diabetes mellitus
Optimising sleep duration and quality and the management
of sleep disorders was discussed as a therapeutic approach
in six guidelines [34,43,50,57,60,61]. Three guidelines recom-
mended optimal sleep duration as a therapeutic target of life-
style intervention and self-management education [43,50,57]
with one guideline identifying optimal sleep as a means of
achieving glycaemic targets in T2DM [57]. One guideline sug-
gested considering OSA if patients were having difficulty
achieving treatment goals [61]. One guideline identified how
successful treatment of OSA can lower fasting and post-
prandial glucose levels and HbA1C equivalent to, or more
than, oral medication with a concomitant improvement in
cardiovascular outcomes [57]. Another CPG identifies that
sleep disruption due to OSA or any other reason, can result
in aggravated insulin resistance and hyperglycaemia [34].
One guideline identified the mixed evidence on glycaemic
control effects of OSA treatment [60].
3.3.3. Sleep and comorbidities as a risk factor for type 2
diabetes mellitus
Sub-optimal sleep was identified as potentially causing or
contributing to a number of diabetic comorbidities in 12
(86%) guidelines [34,38,42,43,48,50,55–57,60–62]. Six guidelines
(43%) highlighted the role of OSA in cardiovascular diseases
[34,50,56,60–62]. Two guidelines identified ‘sleep disruption
of any cause’ as aggravating hypertension [34,57]. Obstructive
sleep apnoea was described as prevalent in two CPGs [60,61]
and an associated risk factor for hypertension (HTN) [60,61]
and cardiovascular disease [56,60,61]. One guideline sug-
gested testing for OSA in T2DM with persistent hypertension
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Table 3 – Strength of evidence for sleep-related recommendations.
CPG Sleep Assessment/
Sleep as a risk factor
for T2DM









USA, American Association of Clinical Endocrinologists and
American College of Endocrinology (2015)
[57]
4 4 3 N/A 4
USA, American Diabetes Association (2020)
[60]
2 4 2 N/A 2
Canada, Diabetes Canada (2018)
[38]
2 N/A 2 3 N/A
USA, ICSI Institute for Clinical Systems Improvement (2014)
[61]
1 4 1 N/A N/A
International Diabetes Federation (2014)
[42]
N/A N/A 4 N/A N/A
India, RSSDI (2017)
[43]
N/A 2 2 N/A 4
Japan, Japan Diabetes Society (2016)
[46]
2 N/A N/A N/A 2
USA, Joslin Center (2017)
[62]
1 N/A 1 N/A 4
Malaysia, Ministry of Health, Malaysian Endocrine and
Metabolic Society, Academy of Medicine, Diabetes Malaysia,
Family Medicine Specialists Association of Malaysia (2015)
[48]
N/A N/A 4 N/A N/A
Poland, Diabetes Poland (Polish Diabetes Association) (2019)
[50]
N/A 4 4 N/A 4
Qatar, Clinical Guidelines for the state of Qatar (2016)
[52]
2 N/A N/A N/A N/A
Australia, Royal Australian College of General Practitioners/
Diabetes Australia (2016)
[34]
3 3 3 2 N/A
South Africa, Society for Endocrinology, Metabolism and
Diabetes of South Africa (2017)
[56]
N/A N/A 4 4 N/A
Singapore, Ministry of Health, Singapore (2014)
[55]
N/A N/A 4 N/A N/A
















































[50]. Five guidelines identified a relationship between sleep
and obesity [38,43,57,60,61]. Three of these guidelines focused
on OSA specifically, while one guideline mentioned sleep gen-
erally [43]. Prevalence of OSA among patients with T2DM and
obesity was identified in two CPGs [60,61]. One guideline also
highlighted the presence of OSA may impact the ability to
lose weight in T2DM [38]. Other comorbidities were men-
tioned in relation to sleep. Two guidelines discussed sleep dis-
turbances as an indicator of mental health issues in people
with T2DM, particularly depression [48,55]. Two other guideli-
nes discussed OSA as a risk factor related to erectile dysfunc-
tion in men with T2DM [38,56]. Poor sleep as a result of
painful diabetic neuropathy was discussed in two guidelines
[42,43].
3.3.4. Sleep and driving as a risk factor for type 2 diabetes
mellitus
Three CPGs discussed the effects of sleep on the ability to
drive [34,38,56]. All three guidelines mentioned the potentially
adverse impact on driving capabilities which may result due
to OSA and the associated sleepiness. Assessment and man-
agement of OSA is an important aspect in regard to ensuring
fitness to drive among people with diabetes [56].
3.3.5. Shift work and type 2 diabetes
Five CPGs mentioned the impact of sleep timing and/or shift
work on Type 2 Diabetes management [43,46,50,57,62]. Night
shift occupation was noted as a risk factor for prediabetes




Records idenfied through database 














GIN n=44, Guideline 
Central n=9, Hand 
























Titles and abstracts 
screened
n=786
Full text arcles 
searched for CPGs 
n=36




Wrong publicaon type 
n=7
Duplicate, i.e. CPG 
sourced from GIN or 
other sites n=9
Wrong CPG n=5
Pre-2010 or outdated 
n=3





Hand searched and society websites n=24
Total Clinical Pracce Guidelines included for analysis
n=35
Total Clinical Pracce Guidelines reviewed due to inclusion of sleep
n=14
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obtained from one article.
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in three guidelines [46,50,57]. Two guidelines [50,62] recom-
mended special attention be given to shift workers by clini-
cians in regard to antidiabetic drug choice, tailoring care to
their schedules and assessing the impact of shift work on
their glycaemic control. It was also advised that shift workers
with diabetes intensively self-monitor their blood sugar while
working [50]. One guideline also suggested, where possible,
employers should support employeeswith diabetes to discon-
tinue shift work, if they chose to do so [50]. One guideline [43]
acknowledged the high risk of hypoglycaemia to shift workers
with diabetes that fast during Ramadan.[41]
4. Discussion
The review of CPGs identified that the impact of sleep and
sleep disorders on diabetes and its complications is recog-
nised in approximately 40% of diabetes CPGs reviewed. The
key areas that were identified in CPGs reflect the various ways
in which sleep and its disorders can affect people with T2DM.
Whilst some CPGs recognised the potential impact of sleep on
T2DM, several did not recommend any assessment of sleep.
There were disagreements amongst guidelines regarding
sleep optimisation or treatment of OSA to improve glycaemic
outcomes. Several guidelines recognised the relationship
between sleep and mental health, particularly depression,
while others highlighted the bidirectional relationship
between sleep and diabetes complications. Driving is a key
issue for those with diabetes and assessing OSA as part of fit-
ness to drive was highlighted.
Obstructive sleep apnoea is a common T2DM co-morbidity
and most CPGs, especially from developed countries, high-
light this common sleep disorder. Firstly, there is evidence
that even snoring (a common symptom of sleep apnoea) is
associated with glycaemic abnormalities. Hyperglycaemia is
also associatedwith apnoea-hypopnoea index (AHI), the com-
mon measure of OSA as well as hypoxaemia [23,68,69].
Obstructive sleep apnoea is highly prevalent amongst people
with T2DM with prevalence ranging from about 20% in pri-
mary care to over 80% in secondary care [70,71]. Obstructive
sleep apnoea not only increases diabetes risk [72], but also
impacts on diabetes complications [20,22,24] since it shares
several pathophysiological pathways [28] with diabetic
macro- and micro- vascular disease. Receiving treatment for
OSA is associated with improved glycaemic control [73],
although evidence from randomised clinical trials are incon-
clusive [74,75]. Obstructive sleep apnoea also results in sev-
eral co-morbidities that accompany T2DM such as
hypertension, atrial fibrillation, depression, erectile dysfunc-
tion, and gastro-oesophageal reflux disease. Therefore, iden-
tifying and treating OSA may benefit several co-morbidities
associated with T2DM. It is of interest that not all CPGs high-
light OSA or recommend screening for OSA or provide a clear
pathway for OSA assessment for those with T2DM, particu-
larly given its prevalence. Lack of screening recommenda-
tions could be related to lack of easy access to sleep testing.
However, it is possible to conduct an initial screen in the clinic
using questionnaires such as the STOP-BANG questionnaire
[76]. Home sleepmonitoring devices are increasingly available
at low cost obviating the need for laboratory sleep testing to
identify those with OSA. Close collaboration between T2DM,
sleep, and other related specialties (e.g. respiratory medicine)
should facilitate the identification and optimisation of OSA
treatment amongst those with T2DM.
Shift work has been associated with both the development
of T2DM and poor glycaemic control in thosewith T2DM. Over
time, shift work has become ubiquitous with recent estimates
that one fifth of employees in Europe and United States are
shift workers [77]. Shift work results in altered timing of sleep
and eating and therefore altered circadian rhythms. Previous
systematic reviews have identified a requirement to integrate
recommendations around glycaemic control and shift work
into clinical practice guidelines [78], however, according to
this review, there remains a sparsity of such guidance with
only 14% of included guidelines including content pertinent
to shift work.
The impact of sleep duration and quality on glycaemic
control has been noted by several observational studies. How-
ever, there are several deficiencies amongst these studies
which may impede translation from research to practice. In
particular, sleep duration and quality are based on self-
report in many studies rather than using objective measures
of sleep. Because of this, there is insufficient attention within
CPGs for assessing sleep duration and quality. While greater
evidence is needed regarding sleep improvement or manipu-
lation to improve glycaemic control, paying attention to sleep
duration and quality could highlight several T2DM co-
morbidities that are associated with disturbed sleep such as
depression, anxiety, and painful neuropathy. Recurrent hypo-
glycaemia could also disturb sleep and may need further
investigation. Quality of life and sleepiness can be improved
by identifying those with sleep disturbance related to shift
work. Furthermore, assessment and management of sleep is
cost-effective, quick and associated with no adverse out-
comes. Therefore, there is a need for greater emphasis on
the assessment of the impact of sleep duration and quality
amongst CPGs.
5. Conclusion
In conclusion, there is some recognition of the impact of sleep
duration and quality on diabetes and diabetes associated co-
morbidities, but this is less detailed and not covered by many
guidelines. While most CPGs recognise OSA as a key T2DM
morbidity, this is not recognised by all CPGs and there is
insufficient clear guidance regarding screening and treatment
of those with diabetes and OSA. There is a need for greater
advocacy for the impact of sleep and its disorders on diabetes
and diabetes co-morbidities.
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